Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Follow-Up Shows Favorable Results With Acalabrutinib in MCL

Publish date:: October 8, 2019

Key clinical point: Acalabrutinib monotherapy can produce durable responses in relapsed/refractory mantle cell lymphoma.

Major finding: The overall response rate was 81%, and the median duration of response was 26 months.

Study details: A phase 2 study of 124 patients with relapsed/refractory mantle cell lymphoma.

Disclosures: The study was sponsored by Acerta Pharma, a member of the AstraZeneca Group. The researchers reported relationships with AstraZeneca/Acerta Pharma and many other companies.

Citation:

Wang M et al. Leukemia. 2019 Sep 26. doi: 10.1038/s41375-019-0575-9.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in B Cell Lymphoma

Four-item prognostic index predicts survival in adult Burkitt lymphoma,

Synthetic lethality: Triple combination is a viable strategy for B-cell malignancies,

ZUMA-12 study shows frontline axi-cel has substantial activity in high-risk large B-cell lymphoma,

Pediatric regimens better for adolescents/young adults with aggressive B-cell NHL,

Bispecific antibody odronextamab demonstrates durable complete responses in refractory NHL,